000790 Chengdu huasun technology group Inc., LTD.
- 3.85
- +0.05+1.32%
Chengdu huasun technology group Inc., LTD. News
[BT Financial Report Momentary Analysis] In-depth Analysis of Huashen Technology's 2023 Report: Challenges and Opportunities Coexist
As an enterprise with an important position in the fields of medicine and construction steel structures, Huashen Technology (stock code: 000790) attracted market attention for its business activities in 2023. Over the past year, Huashen Technology has faced multiple challenges such as policy adjustments in the pharmaceutical industry, increased market competition, and rising raw material costs. At the same time, it is also actively seeking transformation and breakthroughs to find new growth points in the midst of change. Judging from balance and liability data, Huashen Technology's total assets increased from 1,677 billion yuan in 2022 to 2,133 billion yuan in 2023, an increase of 27.22%, showing the size of the company
Huashen Technology (000790.SZ): Huashen Steel plans to undertake a professional steel structure subcontract project for the Jiangsu Liansheng Heterojunction (HJT) solar cell production project contracted by Rongji Construction
Gelonghui, May 16, 丨 Huashen Technology (000790.SZ) announced that the company's wholly-owned subsidiary, Sichuan Huashen Steel Structure Co., Ltd. (“Huashen Steel Structure”), intends to undertake the steel structure professional subcontract project for the Jiangsu Liansheng Technology Co., Ltd. heterojunction (HJT) solar cell production project contracted by Emeishan Rongji Construction Co., Ltd. (“Rongji Construction”), and signed the “Jiangsu Liansheng Technology Co., Ltd. Heterogeneous Junction (HJT) Solar Cell Production Project Steel Structure Professional Subcontract” with conditions. 1 billion yuan (tax included ), the final settlement price failed
The indirect controlling shareholders of Huashen Technology (000790.SZ) increased their total shares by 1%
According to the Zhitong Finance App, Huashen Technology (000790.SZ) issued an announcement. As of the disclosure date of this announcement, the implementation period of this increase plan has passed. Chengdu Yuanhong Biotechnology Co., Ltd., the indirect controlling shareholder of the company, has increased its holdings of the company's shares by 6,280,000 shares through centralized bidding transactions through the Shenzhen Stock Exchange trading system, accounting for 1% of the current total share capital of the company, and the total amount paid is about 197636 million yuan. The current plan to increase its holdings has not yet been completed, and Chengdu Yuanhong will continue to increase its holdings in accordance with the holdings increase plan.
We Think You Can Look Beyond Chengdu Huasun Technology Group's (SZSE:000790) Lackluster Earnings
The market was pleased with the recent earnings report from Chengdu huasun technology group Inc. , LTD. (SZSE:000790), despite the profit numbers being soft. We think that investors might be looking
Huasun Technology to Cancel 3.8 Million Repurchased Shares
Chinese drugmaker Chengdu Huasun Technology Group (SHE:000790) will cancel 3.8 million shares that the company repurchased, the company said in its filing on the Shenzhen Stock Exchange. The shares, w
Huashen Technology (000790.SZ): Net profit of 2.2798 million yuan in the first quarter decreased by 28.96% year-on-year
Gelonghui, April 29 | Huashen Technology (000790.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 179 million yuan, down 18.62% year on year; net profit attributable to shareholders of listed companies was 2.2798 million yuan, down 28.96% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1.9454 million yuan, down 30.92% year on year; basic earnings per share were 0.0036 yuan.
Huashen Technology (000790.SZ): Received a government subsidy of 11.2312 million yuan
Gelonghui, April 1, 丨 Huashen Technology (000790.SZ) announced that on March 29, 2024, Tibet Kangyu Pharmaceutical Co., Ltd., the holding subsidiary of Chengdu Huashen Technology Group Co., Ltd. received a special fund of 11.2312 million yuan to support industries related to revenue, accounting for 27.25% of the company's 2022 audited net profit attributable to shareholders of listed companies
Huashen Technology (000790.SZ): As of March 20, 2024, the number of shareholders of the company was 3,9972
Gelonghui March 29 | Huashen Technology (000790.SZ) said on the investor interactive platform that as of March 20, 2024, the number of shareholders of the company was 39,972.
Huashen Technology (000790.SZ) received an indirect controlling shareholder Chengdu Yuanhong's shares increased by 1%
Huashen Technology (000790.SZ) announced that the company received indirect holding shares of the company on February 7, 2024...
Huashen Technology (000790.SZ): The indirect controlling shareholder plans to increase the company's shares by 30 million yuan to 60 million yuan
Gelonghui, February 5, 丨 Huashen Technology (000790.SZ) announced that the company (hereinafter referred to as the “Company”) received the “Notice Letter on the Plan to Increase the Company's Shares” submitted by Chengdu Yuanhong Biotechnology Co., Ltd. (hereinafter referred to as “Chengdu Yuanhong”), the indirect controlling shareholder of the company on February 5, 2024. Based on confidence in the company's future stable development and recognition of long-term investment value, Chengdu Yuanhong, as the main shareholder, plans to increase the company's shares through centralized bidding transactions or bulk transactions within 6 months from February 6, 2024. The proposed increase in holdings is not less than RMB 30 million, no
Some Chengdu Huasun Technology Group Inc. , LTD. (SZSE:000790) Shareholders Look For Exit As Shares Take 28% Pounding
Chengdu huasun technology group Inc. , LTD. (SZSE:000790) shareholders that were waiting for something to happen have been dealt a blow with a 28% share price drop in the last month. Instead of bei
Investors One-year Losses Continue as Chengdu Huasun Technology Group (SZSE:000790) Dips a Further 14% This Week, Earnings Continue to Decline
It's easy to feel disappointed if you buy a stock that goes down. But sometimes broader market conditions have more of an impact on prices than the actual business performance. The Chengdu huasun t
Huashen Technology (000790.SZ): Currently, the Shandong Lingkai project team is making every effort to promote project construction and is scheduled to be put into operation in the first half of 2024
Gelonghui December 28 丨 An investor asked Huashen Technology (000790.SZ) on the investor interactive platform, “Has Shandong Lingkai put into production?” The company replied that at present, the Shandong Lingkai project team is making every effort to promote project construction and is scheduled to be put into operation in the first half of 2024.
Huashen Technology (000790.SZ): Produces roxithromycin-related products
Glonghui November 17: Some investors asked Huashen Technology (000790.SZ) on the investor interactive platform, “Does your company produce roxithromycin-related products?” The company replied that it produces roxithromycin related products.
Chengdu Huasun Technology to Construct Drug Ingredient Plant for 480 Million Yuan
Chinese drugmaker Chengdu Huasun Technology Group (SHE:000790) plans to invest up to 480 million yuan through subsidiary Shandong Lingkai Pharmaceutical to construct a production line for raw drug ing
Shandong Lingkai, a subsidiary of Huashen Technology (000790.SZ), plans to invest no more than 480 million yuan to invest 15,000 tons/year for a green production base project for high-end new materials and APIs (including pharmaceutical intermediates) (ph
Huashen Technology (000790.SZ) announced that the company will hold the 13th board meeting on November 6, 2023...
Huashen Technology (000790.SZ) released the first three quarter results, net profit of RMB 21.886 million, a decrease of 18.69%
Huashen Technology (000790.SZ) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 6...
Chengdu Huasun Technology Group Inc. , LTD.'s (SZSE:000790) Business Is Trailing The Industry But Its Shares Aren't
With a median price-to-sales (or "P/S") ratio of close to 3.6x in the Pharmaceuticals industry in China, you could be forgiven for feeling indifferent about Chengdu huasun technology group Inc. , LTD.
Huashen Technology (000790.SZ): The integrated project of raw materials and chemical generic drugs has now initiated research on 6 chemical generic drug projects
On July 24, | An investor asked Huashen Technology (000790.SZ) on the Investor Interactive Platform, “May I ask your company to launch the “Raw Chemical Generic Drug” integrated project (first batch of generic drugs) research. What is the current progress?” The company replied that the integrated raw materials and chemical generic drug project has now initiated 6 chemical generic drug project studies, 3 of which have completed laboratory research.
Chengdu Huasun Technology Group Inc. , LTD.'s (SZSE:000790) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Chengdu huasun technology group (SZSE:000790) has had a great run on the share market with its stock up by a significant 17% over the last three months. However, we decided to pay attention to the c
Analysis
Price Target
No Data
